Client and investment firm Taiwania Capital led a funding round of more than $17 million for leading drug delivery platform company Windgap Medical. The life sciences innovator is commercializing a drug autoinjector that is supported by an ongoing grant from the National Institutes of Health.

Taiwania Capital focuses on investing in early-stage companies, with a mission to establish partnerships with companies worldwide and boost Taiwan’s economic growth. Launched with $200 million, Fund II invests in startups in pharmaceutical product research and development, gene/cell therapy and medical technology.

Procopio attorneys supporting Taiwania Capital included Xiaofan “Frank” Yang and Dennis Doucette.

Learn more in Windgap Medical press release.